That meant many women who were used to a dosage of 10 mg would potentially have to make do with 5 mg in the future.
But is that unfair to female insomniacs? Or is it justified considering the known risk of next-morning impairment, and particularly the potential for driving accidents?
To answer these questions, some background to the issue is needed.
Note: I’ve since updated this article to reflect the current guidance that the dosage can be increased if 5 mg is ineffective. See below for more information.
The new ambien dosage
The FDA announced that it had told manufacturers of sleeping pills containing Zolpidem, such as Ambien, that they should reduce the recommended dosage.
The standard recommended Ambien dosage for women was reduced from 10 mg to 5 mg. And for extended release formulations, the dosage was reduced from 12.5 mg to 6.25 mg.
For men, on the other hand, the FDA asked manufactures to change the labeling so that prescribers consider lowering the dosage to 5 mg and 6.25 mg respectively.
In addition to the dosage being lowered, the FDA further adds that medical practitioners should advise patients taking sleeping pills containing Zolpidem that they are at a higher risk of impaired mental alertness.
Clinical trials showing worse driving skills
The reason behind this change is that clinical trials and driving simulation studies have apparently shown that some women perform certain tasks, such as driving, less well the morning after taking Ambien.
They found that women eliminate Zolpidem slower than men, though men also have a small chance of driving worse the next morning.
This was widely reported in the news, but what’s particularly interesting to me is the reaction from many people who rely on such sleeping pills to manage their insomnia.
The comments sections of online news articles show a strong reaction from people who believe that they tolerate their higher Ambien dosage very well. Many people feel they pose no potential threat to others from activities such as driving.
Unsurprisingly, the manufacturers of Ambien, Sanofi, also released a statement saying that they believe Ambien to be safe according to their clinical data and 20 years of use by millions of people.
Ambien has indeed had a great deal of testing by people – it’s the most popular sleeping pill available in many countries. And in 2011 in the United States, 44.8 million prescriptions were written for sleeping pills containing Zolpidem.
With so much apparently safe usage of the higher Ambien dosage and other Zolpidem containing sleeping pills, how bad could the results of these simulation studies have been?
Too much Ambien in the bloodstream the next morning
The FDA reports that recent driving simulation studies found that if people have over 50 ng/mL Zolpidem in the blood, then there’s an increased risk of having a driving accident.
The simulation studies involved 250 men and 250 women taking a dose of 10mg Ambien.
8 hours after dosage, they discovered that 15% of women and 3% of men exceeded the levels of 50 ng/mL, with 4 people having more than 90 ng/mL.
The results of the group taking the extended release 12.5mg show even higher incidents of elevated Zolpidem amounts in the blood – 33% of women and 25% of men.
What the manufacturer of Ambien says
This issue isn’t new news, with the following statement appearing on Sanofi’s website:
Complex behaviors such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported with sedative-hypnotics, including zolpidem
They then go on to say:
Due to the risk to the patient and the community, discontinuation of Ambien CR should be strongly considered for patients who report a “sleep-driving” episode.
So should people be given a chance to use the old Ambien dosage, and hope that if they are one of the few people (and admittedly, research does suggest that thankfully sleep-driving is very rare) then they will be responsible to themselves and others and discontinue the drug?
Or should anything that carries such a potentially life threatening risk be seriously addressed?
Well, perhaps the answer can be found in another statement on Sanofi’s website:
As with “sleep-driving”, patients usually do not remember these events.
So if patients don’t always remember that they were sleep-driving, how can they be expected to report the episode and therefore discontinue the drug?
Why insomniacs feel it’s unfair
When reading the many frustrated comments written on news websites by insomniacs who previously had the higher Ambien dosage, 5 main points come across:
1. That they feel they shouldn’t be punished because the drug can have dangerous effects on a minority of people.
2. That the dosage should be tailored to each individual’s needs.
3. That they believe some people don’t follow the guidance properly (taking the sleeping pill at the wrong time, or mixing it with alcohol) and this is why dangerous behavior can occur.
4. That if they don’t get a good night’s sleep, they are even more at risk of having a driving accident.
5. Some people don’t drive anyway, so why should they suffer because of those that do?
While it’s understandable that people who feel Ambien has transformed their lives after suffering from insomnia, the risks have to be balanced.
Although the FDA states that only a few dozen incidents of sleep-driving involving Ambien have been reported, they suspect there have been many more unreported cases. And many of these cases could well have been catastrophic in their consequences.
Update – a tailored approach
The FDA, however, later released updated advice allowing some room for tailoring the dosage to the individual – which is what many women who rely on the higher dosage to sleep properly felt would be right to do.
The key points to note are that the wording changed from ‘recommended dose’ to ‘recommended initial dose’, and that the dose can be increased if necessary.
So the FDA website currently states the following advice:
The recommended initial dose of zolpidem extended-release (Ambien CR) is 6.25 mg for women and either 6.25 or 12.5 mg for men. If the lower doses (5 mg for immediate-release, 6.25 mg for extended-release) are not effective, the dose can be increased to 10 mg for immediate-release products and 12.5 mg for zolpidem extended-release. However, use of the higher dose can increase the risk of next-day impairment of driving and other activities that require full alertness.
The current Ambien label
If you’d like to keep up to date with any changes to the recommended dosage, you can do so by looking at the online FDA Ambien label.
At the time of writing, the section on dosage and administration looks like this:
Do you take Ambien? What dosage do you take, and do you feel it works for you? Do you find it affects your ability to drive or do other tasks that need you to be particularly alert in the morning?
Please leave a comment below with your thoughts on the Ambien dosage.